Mast cell activation syndromes: Definition and classification

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 68, Issue 4, 2013, Pages 417-424

  Valent, P ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

allergic reactions; classification; criteria; IgE; mast cells

Indexed keywords

ALLERGEN; IMMUNOGLOBULIN E; TRYPTASE;

ABDOMINAL CRAMP; ADRENAL INSUFFICIENCY; ALLERGY; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; AORTA STENOSIS; BACTERIAL INFECTION; CELL ACTIVATION; CELL COUNT; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM TUMOR; CHAGAS DISEASE; COMORBIDITY; CROHN DISEASE; DEHYDRATION; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; ENCEPHALITIS; ENDOCARDITIS; ENTERITIS; ENZYME BLOOD LEVEL; EPILEPSY; FAINTNESS; FATIGUE; FLUSHING; FOOD POISONING; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL INFECTION; GENE MUTATION; GENETIC PREDISPOSITION; HEADACHE; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; HYPOPITUITARISM; HYPOTENSION; HYPOTHYROIDISM; IMMUNOPATHOLOGY; INFLAMMATION; INTOXICATION; LABORATORY TEST; LUNG INFARCTION; LUPUS ERYTHEMATOSUS; MAST CELL; MAST CELL ACTIVATION; MAST CELL ACTIVATION SYNDROME; MASTOCYTOSIS; MENORRHAGIA; NAUSEA; NEUROLOGIC DISEASE; NOSE OBSTRUCTION; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; PRURITUS; PSYCHOSIS; RECURRENT DISEASE; REVIEW; SEPTIC SHOCK; SHOCK; SKIN DISEASE; TACHYCARDIA; ULCERATIVE COLITIS; URTICARIA; VIRUS INFECTION; WHEEZING;

COMORBIDITY; DIAGNOSIS, DIFFERENTIAL; HUMANS; MAST CELLS; MASTOCYTOSIS; SYNDROME;

EID: 84875421013     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12126     Document Type: Review

References (68)

1. Schwartz LB,. Mast cells and basophils. Clin Allergy Immunol 2002; 16: 3-42.
2. Metcalfe DD,. Mast cells and mastocytosis. Blood 2008; 112: 946-956.
3. Galli SJ, Tsai M,. Mast cells in allergy and infection: versatile effector and regulatory cells in innate and adaptive immunity. Eur J Immunol 2010; 40: 1843-1851.
4. Bossi F, Frossi B, Radillo O, Cugno M, Tedeschi A, Riboldi P, et al. Mast cells are critically involved in serum-mediated vascular leakage in chronic urticaria beyond high-affinity IgE receptor stimulation. Allergy 2011; 66: 1538-1545.
5. Galli SJ, Tsai M,. IgE and mast cells in allergic disease. Nat Med 2013; 18: 693-704.
6. Kinet JP,. The high-affinity IgE receptor (Fc epsilon RI): from physiology to pathology. Annu Rev Immunol 1999; 17: 931-972.
7. Nadler MJ, Matthews SA, Turner H, Kinet JP,. Signal transduction by the high-affinity immunoglobulin E receptor Fc epsilon RI: coupling form to function. Adv Immunol 2000; 76: 325-355.
8. Gibbs BF,. Human basophils as effectors and immunomodulators of allergic inflammation and innate immunity. Clin Exp Med 2005; 5: 43-49.
9. Marone G, Spadaro G, Patella V, Genovese A,. The clinical relevance of basophil releasability. J Allergy Clin Immunol 1994; 94: 1293-1303.
10. Kepley CL, Youssef L, Andrews RP, Wilson BS, Oliver JM,. Multiple defects in Fc epsilon RI signaling in Syk-deficient nonreleaser basophils and IL-3-induced recovery of Syk expression and secretion. J Immunol 2000; 165: 5913-5920.
11. MacDonald SM, Vonakis BM,. Association of the Src homology 2 domain-containing inositol 5' phosphatase (SHIP) to releasability in human basophils. Mol Immunol 2002; 38: 1323-1327.
12. Okayama Y, Kashiwakura JI, Matsuda A, Sasaki-Sakamoto T, Nunomura S, Yokoi N, et al. The interaction between Lyn and FcεRIβ is indispensable for FcεRI-mediated human mast cell activation. Allergy 2012; 67: 1241-1249.
13. Havard S, Scola AM, Kay LJ, Ishmael SS, MacGlashan DW Jr, Peachell PT,. Characterization of syk expression in human lung mast cells: relationship with function. Clin Exp Allergy 2011; 41: 378-388.
14. Valent P, Besemer J, Muhm M, Majdic O, Lechner K, Bettelheim P,. Interleukin 3 activates human blood basophils via high-affinity binding sites. Proc Natl Acad Sci (USA) 1989; 86: 5542-5546.
15. Bischoff SC, Dahinden CA,. c-kit ligand: a unique potentiator of mediator release by human lung mast cells. J Exp Med 1992; 175: 237-244.
16. Sperr WR, Czerwenka K, Mundigler G, Müller MR, Semper H, Klappacher G, et al. Specific activation of human mast cells by the ligand for c-kit: comparison between lung, uterus and heart mast cells. Int Arch Allergy Immunol 1993; 102: 170-175.
17. Komai-Koma M, Brombacher F, Pushparaj PN, Arendse B, McSharry C, Alexander J, et al. Interleukin-33 amplifies IgE synthesis and triggers mast cell degranulation via interleukin-4 in naïve mice. Allergy 2012; 67: 1118-1126.
18. Peavy RD, Metcalfe DD,. Understanding the mechanisms of anaphylaxis. Curr Opin Allergy Clin Immunol 2008; 8: 310-315.
19. Metcalfe DD, Peavy RD, Gilfillan AM,. Mechanisms of mast cell signaling in anaphylaxis. J Allergy Clin Immunol 2009; 124: 639-646.
20. Kalesnikoff J, Galli SJ,. Anaphylaxis: mechanisms of mast cell activation. Chem Immunol Allergy 2010; 95: 45-66.
21. Akin C, Scott LM, Kocabas CN, Kushnir-Sukhov N, Brittain E, Noel P, et al. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis. Blood 2007; 110: 2331-2333.
22. Sonneck K, Florian S, Müllauer L, Wimazal F, Födinger M, Sperr WR, et al. Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: monoclonal mast cell activation syndrome. Int Arch Allergy Immunol 2007; 142: 158-164.
23. Bonadonna P, Perbellini O, Passalacqua G, Caruso B, Colarossi S, Dal FiorD, et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol 2009; 123: 680-686.
24. Hamilton MJ, Hornick JL, Akin C, Castells MC, Greenberger NJ,. Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations. J Allergy Clin Immunol 2011; 128: 147-152.
25. Valent P, Horny HP, Triggiani M, Arock M,. Clinical and laboratory parameters of mast cell activation as basis for the formulation of diagnostic criteria. Int Arch Allergy Immunol 2011; 156: 119-127.
26. Akin C, Valent P, Metcalfe DD,. Mast cell activation syndrome: proposed diagnostic criteria. J Allergy Clin Immunol 2010; 126: 1099-1104.
27. Valent P, Akin C, Arock M, Brockow K, Butterfield JH, Carter MC, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 2012; 157: 215-225.
28. Serafin WE, Austen KF,. Mediators of immediate hypersensitivity reactions. N Engl J Med 1987; 317: 30-34.
29. Holgate ST, Robinson C, Church MK,. The contribution of mast cell mediators to acute allergic reactions in human skin and airways. Allergy 1988; 43 (S5): 22-31.
30. Schwartz LB, Metcalfe DD, Miller JS, Earl H, Sullivan T,. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med 1987; 316: 1622-1626.
31. Shanmugam G, Schwartz LB, Khan DA,. Prolonged elevation of serum tryptase in idiopathic anaphylaxis. J Allergy Clin Immunol 2006; 117: 950-951.
32. Schwartz LB,. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am 2006; 26: 451-463.
33. Ferrer M, Nuñez-Cõrdoba JM, Luquin E, Grattan CE, De la Borbolla JM, Sanz ML, et al. Serum total tryptase levels are increased in patients with active chronic urticaria. Clin Exp Allergy 2010; 40: 1760-1766.
34. Vegh AB, George KC, Lotfi-Emran S, Butler NE, Schwartz LB,. Total tryptase levels indicate risk for systemic reactions to rush immunotherapy and mast cell activation. Ann Allergy Asthma Immunol 2011; 106: 342-343.
35. Alvarez-Twose I, Vañõ-Galván S, Sánchez- Muñoz L, Morgado JM, Matito A, Torrelo A, et al. Increased serum baseline tryptase levels and extensive skin involvement are predictors for the severity of mast cell activation episodes in children with mastocytosis. Allergy 2012; 67: 813-821.
36. Irani AA, Schechter NM, Craig SS, De Blois G, Schwartz LB,. Two types of human mast cells that have distinct neutral protease compositions. Proc Natl Acad Sci (USA) 1986; 83: 4464-4468.
37. Schwartz LB,. Tryptase, a mediator of human mast cells. J Allergy Clin Immunol 1990; 86: 594-598.
38. Castells MC, Irani AM, Schwartz LB,. Evaluation of human peripheral blood leukocytes for mast cell tryptase. J Immunol 1987; 138: 2184-2189.
39. Samorapoompichit P, Kiener HP, Schernthaner GH, Jordan JH, Agis H, Wimazal F, et al. Detection of tryptase in cytoplasmic granules of basophils in patients with chronic myeloid leukemia and other myeloid neoplasms. Blood 2001; 98: 2580-2583.
40. Jogie-Brahim S, Min HK, Fukuoka Y, Xia HZ, Schwartz LB,. Expression of alpha-tryptase and beta-tryptase by human basophils. J Allergy Clin Immunol 2004; 113: 1086-1092.
41. Kanthawatana S, Carias K, Arnaout R, Hu J, Irani AM, Schwartz LB,. The potential clinical utility of serum alpha-protryptase levels. J Allergy Clin Immunol 1999; 103: 1092-1099.
42. Lin RY, Schwartz LB, Curry A, Pesola GR, Knight RJ, Lee HS, et al. Histamine and tryptase levels in patients with acute allergic reactions: an emergency department-based study. J Allergy Clin Immunol 2000; 106: 65-71.
43. Keyzer JJ, de Monchy JG, van Doormaal JJ, van VoorstVader PC,. Improved diagnosis of mastocytosis by measurement of urinary histamine metabolites. N Engl J Med 1983; 309: 1603-1605.
44. Watkins J, Wild G,. Improved diagnosis of anaphylactoid reactions by measurement of serum tryptase and urinary methylhistamine. Ann Fr Anesth Reanim 1993; 12: 169-172.
45. Lin RY, Schwartz LB, Curry A, Pesola GR, Knight RJ, Lee HS, et al. Histamine and tryptase levels in patients with acute allergic reactions: an emergency department-based study. J Allergy Clin Immunol 2000; 106: 65-71.
46. Awad JA, Morrow JD, Roberts LJ,. Detection of the major urinary metabolite of prostaglandin D2 in the circulation: demonstration of elevated levels in patients with disorders of systemic mast cell activation. J Allergy Clin Immunol 1994; 93: 817-824.
47. Ono E, Taniguchi M, Mita H, Akiyama K,. Salicylamide-induced anaphylaxis: increased urinary leukotriene E4 and prostaglandin D2 metabolite. Allergy 2008; 63: 480-482.
48. Knol EF, Mul FP, Jansen H, Calafat J, Roos D,. Monitoring human basophil activation via CD63 monoclonal antibody 435. J Allergy Clin Immunol 1991; 88: 328-338.
49. Hauswirth AW, Natter S, Ghannadan M, Majlesi Y, Schernthaner GH, Sperr WR, et al. Recombinant allergens promote expression of CD203c on basophils in sensitized individuals. J Allergy Clin Immunol 2002; 110: 102-109.
50. Bühring HJ, Streble A, Valent P,. The basophil-specific ectoenzyme E-NPP3 (CD203c) as a marker for cell activation and allergy diagnosis. Int Arch Allergy Immunol 2004; 133: 317-329.
51. Valent P, Hauswirth AW, Natter S, Sperr WR, Bühring HJ, Valenta R,. Assays for measuring in vitro basophil activation induced by recombinant allergens. Methods 2004; 32: 265-270.
52. Hauswirth AW, Escribano L, Prados A, Nuñez R, Mirkina I, Kneidinger M, et al. CD203c is overexpressed on neoplastic mast cells in systemic mastocytosis and is upregulated upon IgE receptor cross-linking. Int J Immunopathol Pharmacol 2008; 21: 797-806.
53. de Weck AL, Sanz ML, Gamboa PM, Aberer W, Bienvenu J, Blanca M, et al. Diagnostic tests based on human basophils: more potentials and perspectives than pitfalls. Int Arch Allergy Immunol 2008; 146: 177-189.
54. Valent P, Akin C, Escribano L, Födinger M, Hartmann K, Brockow K, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007; 37: 435-453.
55. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci (USA) 1995; 92: 10560-10564.
56. Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG, et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996; 12: 312-314.
57. Fritsche-Polanz R, Jordan JH, Feix A, Sperr WR, Sunder-Plassmann G, Valent P, et al. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol 2001; 113: 357-364.
58. Féger F, Ribadeau Dumas A, Leriche L, Valent P, Arock M,. Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol 2002; 127: 110-114.
59. Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993; 92: 1736-1744.
60. Mayerhofer M, Gleixner KV, Hoelbl A, Florian S, Hoermann G, Aichberger KJ, et al. Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. J Immunol 2008; 180: 5466-5476.
61. Sotlar K, Escribano L, Landt O, Möhrle S, Herrero S, Torrelo A, et al. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol 2003; 162: 737-746.
62. Bodemer C, Hermine O, Palmérini F, Yang Y, Grandpeix-Guyodo C, Leventhal PS, et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol 2010; 130: 804-815.
63. Arock M, Valent P,. Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev Hematol 2010; 3: 497-516.
64. Metcalfe DD, Schwartz LB,. Assessing anaphylactic risk? Consider mast cell clonality J Allergy Clin Immunol 2009; 123: 687-688.
65. Bonadonna P, Zanotti R, Pagani M, Caruso B, Perbellini O, Colarossi S, et al. How much specific is the association between hymenoptera venom allergy and mastocytosis? Allergy 2009; 64: 1379-1382.
66. Niedoszytko M, de Monchy J, van Doormaal JJ, Jassem E, Oude Elberink JN,. Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy. Allergy 2009; 64: 1237-1245.
67. Bonadonna P, Zanotti R, Müller U,. Mastocytosis and insect venom allergy. Curr Opin Allergy Clin Immunol 2010; 10: 347-353.
68. Wimazal F, Geissler P, Shnawa P, Sperr WR, Valent P,. Severe life-threatening or disabling anaphylaxis in patients with systemic mastocytosis: a single-center experience. Int Arch Allergy Immunol 2012; 157: 399-405.